Dr Gillings is the Co-founder and non-Executive Vice Chair of GHO Capital. She is an industry leader who brings more than 22 years of scientific, pre-clinical/clinical, operational and proven leadership in the biopharmaceutical industry to the firm. Mireille founded and grew HUYA Bioscience International, a leader in accelerating the global development of novel pharmaceutical product opportunities originating in China.
She was the first to in license Chinese innovative products, establish extensive collaborations with Chinese academic and commercial biopharmaceuticals organisations and leverage the Asian tripartite agreement. Mireille and Dennis Gillings realised the need for a European private equity fund specialising in global health opportunities and financially cornerstoned the inception of GHO Capital. Dr Gillings worked as a post-doctoral fellow at Bordeaux University and Scripps Institute and completed her Ph.D. at the Radboud University of Nijmegen.
Mireille is the first woman to be appointed to the board of Quintiles, a Fortune 500 company, since its privatisation and subsequent IPO. She is a member of the Governance, Quality and Nominating Committee. Currently, Mireille is a board member of Senté, Inc. and serves on the Pasteur Institute advisory board. She is fluent in English, Dutch, French and Spanish.
Connect with GHO
GHO value creation
Enablement & Alignment
Capability & Capacity
Building Strategic Footprints
Better, faster + more accessible healthcare